CD47 and diffuse large B-cell lymphoma: Similarly, RTX-47 is a CD47xCD20 BsAb, consisting of a CD47 blocking scFv fused in tandem to a CD20 targeting scFv derived from rituximab [139], which could potentially be useful in the treatment of DLBCL; however, no human trials are yet available.